Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

The Urokinase Receptor (uPAR) as a "Trojan Horse" in Targeted Cancer Therapy: Challenges and Opportunities

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Health-Related Quality of Life and Return to Work after Surgery for Spinal Meningioma: A Population-Based Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Genomic Sub-Classification of Ovarian Clear Cell Carcinoma Revealed by Distinct Mutational Signatures

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Oncomine™ Comprehensive Assay v3 vs. Oncomine™ Comprehensive Assay Plus

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. ANGPTL4: a new mode in the regulation of intravascular lipolysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Expression and one-step purification of active LPL contemplated by biophysical considerations

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The collagen receptor uparap in malignant mesothelioma: A potential diagnostic marker and therapeutic target

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. The Importance of Lipoprotein Lipase Regulation in Atherosclerosis

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

One of the largest challenges to the implementation of precision oncology is identifying and validating selective tumor-driving targets to enhance the therapeutic efficacy while limiting off-target toxicity. In this context, the urokinase-type plasminogen activator receptor (uPAR) has progressively emerged as a promising therapeutic target in the management of aggressive malignancies. By focalizing the plasminogen activation cascade and subsequent extracellular proteolysis on the cell surface of migrating cells, uPAR endows malignant cells with a high proteolytic and migratory potential to dissolve the restraining extracellular matrix (ECM) barriers and metastasize to distant sites. uPAR is also assumed to choreograph multiple other neoplastic stages via a complex molecular interplay with distinct cancer-associated signaling pathways. Accordingly, high uPAR expression is observed in virtually all human cancers and is frequently associated with poor patient prognosis and survival. The promising therapeutic potential unveiled by the pleiotropic nature of this receptor has prompted the development of distinct targeted intervention strategies. The present review will focus on recently emerged cytotoxic approaches emphasizing the novel technologies and related limits hindering their application in the clinical setting. Finally, future research directions and emerging opportunities in the field of uPAR targeting are also discussed.

OriginalsprogEngelsk
Artikelnummer5376
TidsskriftCancers
Vol/bind13
Udgave nummer21
ISSN2072-6694
DOI
StatusUdgivet - 27 okt. 2021

ID: 69168647